SHAREHOLDER ALERT: Robbins LLP Announces That Kadmon Holdings, Inc. (KDMN) is Being Sued for Misleading Shareholders
Ohio Pen/10110828

SAN DIEGO & LORDSTOWN, Ohio--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Kadmon Holdings, Inc. (NASDAQ: KDMN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between October 1, 2020 and March 10, 2021. Kadmon is a biopharmaceutical company that develops small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Kadmon's lead product candidate includes belumosudil (KD025), which is in Phase II clinical development for the treatment of chronic graft-versus-host disease ("cGVHD").

If you suffered a loss due to Kadmon Holdings, Inc.'s misconduct, click here.

Kadmon Holdings, Inc. (KDMN) Misled Investors Regarding its New Drug Submission for its Lead Drug Candidate

More on Ohio Pen

• Over 98% of crypto owners globally don't declare taxes, new report find
• TicTac Group acquires French EdTech company Distrisoft
• Aegis Solis Launches Archive for Non-Coercive AI Ethics and Interpretive Braking
• Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
• Genpak Announces Closure of Utah Manufacturing Facility

According to the complaint, on September 30, 2020, Kadmon announced the submission of a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD with the U.S. Drug and Food Administration ("FDA"). On November 30, 2020, Kadmon announced the FDA's acceptance of the NDA and that the FDA had assigned the NDA a Prescription Drug User Fee Act [PDUFA] target date of May 30, 2021. Throughout the class period, Kadmon touted the drug's trial milestones and efficacy. However, the Company failed to disclose that the NDA was incomplete and/or deficient when submitted and the additional data submitted in support of the NDA materially altered the initial submission, and therefore, the PDUFA target date.

On March 10, 2021, Kadmon announced that the FDA "has extended the review period" for the NDA and that, "[i]n a notice received from the FDA on March 9, 2021, the Company was informed that the [PDUFA] goal date for its Priority Review of belumosudil has been extended to August 30, 2021." Kadmon advised investors that "[t]he FDA extended the PDUFA date to allow time to review additional information submitted by Kadmon in response to a recent FDA information request," and that "[t]he submission of the additional information has been determined by the FDA to constitute a major amendment to the NDA, resulting in an extension of the PDUFA date by three months." On this news, Kadmon's stock price fell $0.52 per share, or 10.57%, to close at $4.40 per share on March 11, 2021. The stock continues to decline.

More on Ohio Pen

• Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
• The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
• Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
• Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
• New Book Reveals The Science Of Predictions

If you purchased shares of Kadmon Holdings, Inc. (KDMN) between October 1, 2020 and March 10, 2021, you have until June 2, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Kadmon Holdings, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

---

Show All News | Report Violation